Brenner Malcolm

CIK 00018180681 companyCAMBRIDGE, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001818068

Recent Transactions

43 trades

Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2024-06-06+35,000→ 100,197 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2023-05-11+35,000→ 65,197 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2022-05-17+27,500→ 27,500 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2021-05-25+22,500→ 22,500 total
Gift
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-05-25−818,663→ 0 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-05$32.19/sh−6,141→ 821,664 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-05$30.39/sh−23,660→ 843,094 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-05$34.40/sh−701→ 818,663 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-05$33.31/sh−2,300→ 819,364 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-05$31.27/sh−15,289→ 827,805 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-04$35.46/sh−13,876→ 886,515 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-04$36.58/sh−8,814→ 877,701 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-04$37.41/sh−10,947→ 866,754 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-04$34.67/sh−15,961→ 900,391 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-03$36.91/sh−3,383→ 930,884 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-03$38.53/sh−8,500→ 916,352 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-03$37.73/sh−6,032→ 924,852 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-02$39.14/sh−1,614→ 934,267 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-02$37.35/sh−3,727→ 943,198 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-02$38.27/sh−7,317→ 935,881 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-01$39.00/sh−8,869→ 946,925 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-03-01$38.39/sh−12,825→ 955,794 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-23$41.19/sh−200→ 968,619 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-23$40.40/sh−1,801→ 968,819 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-23$38.75/sh−2,800→ 974,308 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-23$39.46/sh−3,688→ 970,620 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-22$41.58/sh−2,334→ 986,197 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-22$43.38/sh−310→ 977,108 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-22$42.80/sh−8,779→ 977,418 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-19$41.78/sh−11,990→ 988,531 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-18$39.68/sh−975→ 1,006,303 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-18$40.34/sh−2,800→ 1,003,503 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-18$41.49/sh−2,982→ 1,000,521 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-17$38.66/sh−1,200→ 1,011,243 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-17$39.97/sh−1,000→ 1,010,243 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-17$41.29/sh−2,765→ 1,007,478 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-17$41.99/sh−200→ 1,007,278 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-16$43.13/sh−100→ 1,012,443 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-16$41.75/sh−5,120→ 1,013,543 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-02-16$42.25/sh−1,000→ 1,012,543 total
Conversion
Kalaris Therapeutics, Inc.$KLRS
Series A-3 Convertible Preferred Stock
2020-08-03−1,518,018→ 0 total
Conversion
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2020-08-03+1,018,663→ 1,018,663 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2020-07-29+22,500→ 22,500 total

Companies

Kalaris Therapeutics, Inc.
Director
$KLRS

Recent Filings

Address

C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500

CAMBRIDGE, MA, 02142

View on SEC.gov